PHOENIX MOLECULAR IMAGING
🇺🇸United States
C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression
Phase 2
Withdrawn
- Conditions
- Gliomas
- Interventions
- Drug: Sodium Acetate C11 PET/CT Imaging
- First Posted Date
- 2013-10-14
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Phoenix Molecular Imaging
- Registration Number
- NCT01961934
- Locations
- 🇺🇸
Phoenix Molecular Imaging, Phoenix, Arizona, United States
C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma
Phase 2
Completed
- Conditions
- Prostate CancerProstate Adenocarcinoma
- Interventions
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- Phoenix Molecular Imaging
- Target Recruit Count
- 300
- Registration Number
- NCT01530269
- Locations
- 🇺🇸
Phoenix Molecular Imaging, Phoenix, Arizona, United States
PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- Phoenix Molecular Imaging
- Target Recruit Count
- 2000
- Registration Number
- NCT01304485
- Locations
- 🇺🇸
Phoenix Molecular Imaging, Phoenix, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath